Key result
A modified shock index ≥0.93 at presentation was an independent predictor of six-month all-cause mortality in STEMI patients (adjusted HR 2.00; 95% CI 1.20-3.34; p=0.008).
Why the study?
Does a modified shock index (MSI) ≥0.93 predict six-month mortality in patients presenting with STEMI without cardiogenic shock?
Cohort (n=1,158)
No
Does a modified shock index (MSI) ≥0.93 predict six-month mortality in patients presenting with STEMI without cardiogenic shock?
Hazard Ratio: 2 (95% CI 1.2–3.34)
p-value: p=0.008
A modified shock index ≥0.93 at presentation independently predicts six-month mortality in STEMI patients without cardiogenic shock, serving as a rapid bedside risk stratification tool.
No takes yet. Share an insight, caveat, or question.
May aid bedside stratification in STEMI; hypothesis-generating and requires prospective validation before practice change.
Abreu et al. (2018) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=1,158). Modified shock index (MSI) ≥0.93 vs. Modified shock index (MSI) <0.93 was evaluated on Six-month all-cause mortality (adjusted HR 2.00, 95% CI 1.20-3.34, p=0.008). A modified shock index ≥0.93 at presentation was an independent predictor of six-month all-cause mortality in STEMI patients (adjusted HR 2.00; 95% CI 1.20-3.34; p=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: